Table 1.
Clinical characteristics of 91 MDS patients according to SF3B1 mutation status.
| Characteristic | All Patients (n = 91) |
SF3B1 Wild type (n = 85) |
SF3B1 Mutated (n = 6) |
p-value |
|---|---|---|---|---|
| Age (years) | 0.14 | |||
| Median | 69 | 67 | 77 | |
| Range | 15–91 | 15–91 | 28–83 | |
| Gender | 0.39 | |||
| Female (n) | 53 | 48 | 5 | |
| WHO subtype | 0.003 | |||
| RA no. | 3 | 3 | 0 | |
| RARS (n) | 7 | 3 | 4 | |
| RAEB-I (n) | 3 | 3 | 0 | |
| RAEB-II (n) | 6 | 6 | 0 | |
| RCMD (n) | 52 | 52 | 1 | |
| MDS del (5q) (n) | 3 | 3 | 0 | |
| RCUD (n) | 10 | 10 | 0 | |
| Secondary MDS (n) | 6 | 5 | 1 | |
| Non-classified (n) | 1 | 1 | 0 | |
| Ring sideroblasts | <0.0001 | |||
| Present (n) | 13 | 7 | 6 | |
| Not classified (n) | 6 | 6 | 0 | |
| Karyotype riska | 0.34 | |||
| Low (n) | 19 | 16 | 3 | |
| Intermediate 1 (n) | 46 | 44 | 2 | |
| Intermediate 2 (n) | 6 | 6 | 0 | |
| High (n) | 2 | 2 | 0 | |
| Not classified (n) | 18 | 17 | 1 | |
RA: refractory anemia; RARS: refractory anemia with ring sideroblasts; RAEB-I, II: refractory anemia with excess blasts; RCMD: refractory cytopenia with multilineage dysplasia; MDS del (5q): MDS with isolated 5q deletion; RCUD: refractory cytopenia with unilineage dysplasia.
a
Based on the International Prognostic Scoring System.